How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release
The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC
Roy S. Herbst, MD, PhD, ensign professor of medicine, medical oncology, professor, pharmacology, director, Center for Thoracic Cancers, Assistant Dean for Translational Research, Yale School of Medicine; deputy director, Yale Cancer Center; chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the significance of the FDA approval of adjuvant pembrolizumab (Keytruda) in patients with non–small cell lung cancer (NSCLC).Source: OncLive
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
The VA Launches Largest-Ever Trial on Screening Methods for Liver Cancer
The largest clinical trial in history related to liver cancer screening is launching in 2023, funded by the Department of Veterans Affairs. The project is scheduled to recruit 4,700 veterans with cirrhosis from 47 VA medical centers. Cirrhosis is a major risk factor for liver cancer and affects veterans disproportionally.
Yale Cancer Center Study Characterizes Link Between Drug Resistance and Central Nervous System Relapse
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
New Treatments Keeping Women Alive Longer Through Breast Cancer
Five percent of women diagnosed with breast cancer have metastatic disease, but survival rates are climbing. According to the Breast Cancer Research Foundation, the number of women living with metastatic breast cancer rose to 168,000 last year from 155,000 the year before. New breakthroughs keep women alive longer while researchers race to find the next therapy that will work.Source: WINK
Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.Source: ASCO Daily News
Sickle Cell Cure will be Cost-Effective if Health Disparities Considered -Study Finds
Dec 13 (Reuters) - Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.Source: Reuters
Ignoring Back Pain Can Be a Big Pancreatic Cancer Mistake, Doctors Say
The symptoms of pancreatic cancer may be subtle, varied, or—in the early stages of the disease—non-existent. That's why "pancreatic cancer is the most lethal cancer in the human body, with overall five-year survival rates at just about seven percent despite all the advances over the past decades," according to the Mayo Clinic News Network. "There are no telltale signs for pancreatic cancer, and symptoms like weight loss, abdominal pain, jaundice, and appetite loss are nonspecific."Source: Yahoo Life
Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.Source: SABCS Meeting News
Panel to Examine the Ongoing Evolution of Antibody Drug Conjugates in the Treatment of Breast Cancer
Antibody drug conjugates (ADCs), which use a targeted monoclonal antibody to deliver a cytotoxic payload, are among the most effective breast cancer therapies yet developed. The first Food and Drug Administration approval of an ADC in breast cancer, ado-trastuzumab emtansine, better known as T-DM1, sparked development of numerous new and promising ADCs for breast cancer.Source: SABCS Meeting News
Trastuzumab Deruxtecan Generates OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer
Trastuzumab deruxtecan demonstrated a 34% reduction in the risk of death and a 13-month increase in overall survival compared with treatment of physician’s choice in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who received prior treatment with trastuzumab emtansine.Source: OncLive
Kirstie Alley and Colon Cancer: The Early Signs You Shouldn't Ignore
Actor Kirstie Alley has died after being diagnosed with colon cancer earlier this year. Colon cancer, also known as colorectal cancer, is the third most common type of cancer in the United States and globally. In the U.S. over 151,000 people will develop the disease in 2022.Source: Healthline